AstraZeneca share price: Q2 earnings preview
Astrazeneca Q2 revenue is expected to show strong growth, although an increased cost base will pressure underlying earnings.
When are the AstraZeneca results?
AstraZeneca, the biopharmaceutical company, earnings release date is scheduled for 27 July 2021. The scheduled results will cover the groups second quarter (Q2) and half-year earnings.
What to expect from AstraZeneca results?
While a large Covid-19 vaccine rollout will have boosted revenue for the group, it would have done little for underlying earnings due to the company selling the product as a non-profit item.
Consensus estimates derived from Refinitiv data arrives at the following expectations for Q2 of 2021:
- Revenue $7.530 billion (+20%) year on year (YoY)
- Earnings before interest tax depreciation amortisation (EBITDA) $2.233 billion (-10.75% YoY)
- Earnings per share (EPS) $0.93 (-3.01% YoY)
What is expected to be accretive to future earnings for the group (although may weigh in the short term) is the groups acquisition of biopharmaceutical business Alexion, which was concluded on 21 July 2021, shortly after the reporting quarter.
How to trade AstraZeneca results
A Refinitiv poll of 29 analysts maintain a long-term average rating of ‘buy’ for AstraZeneca (as of 26 July 2021), with 10 of these analysts recommending a strong buy, 16 recommending a buy, 1 hold, 1 sell and 1 strong sell recommendation on the stock.
AstraZeneca share price – technical analysis view
The share price of AstraZeneca continues to trade in an uptrend which has been in place since the beginning of 2021. The price has however started to correct from near-term highs.
Traders respecting the longer-term uptrend will prefer to keep a long bias to trades targeting a retest of the 8770 level, provided that the price does not move to break the confluence of both trend line and horizontal support at the 7800 level. A break of the 7800 level would instead suggest the uptrend to be broken.
- AstraZeneca results are scheduled for release on 27 July 2021
- Q2 revenue of $7.530 billion is expected
- Q2 EBITDA of $2.223 billion is expected
- EPS of $0.93 is expected
- The average broker rating for AstraZeneca is ‘buy’
- The share price of AstraZeneca is currently in a short term correction of a longer-term uptrend
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get commission from just 0.08% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets